Search results
Results From The WOW.Com Content Network
An oncovirus or oncogenic virus is a virus that can cause cancer. [4] This term originated from studies of acutely transforming retroviruses in the 1950–60s, [ 5 ] when the term oncornaviruses was used to denote their RNA virus origin. [ 6 ]
The discovery of specific small-molecule inhibitors that specifically target the different oncogenic proteins and a comprehensive mechanistic analysis of the ways in which oncogenes dysregulate physiological signaling to cause different cancer types and developmental syndromes are potential future advances in the field of cancer research.
An oncolytic virus is a virus that preferentially infects and kills cancer cells. As the infected cancer cells are destroyed by oncolysis , they release new infectious virus particles or virions to help destroy the remaining tumour.
Hepatitis virus-associated hepatocarcinogenesis is a serious health concern. [31] Liver cancer in the United States is primarily due to three main factors: hepatitis C virus (HCV) (22%), hepatitis B virus (HBV) (12%) and alcohol use (47%). [32] In 2017 there will be about 40,710 new cases of liver cancer in the United States. [33]
The Epstein–Barr virus (EBV), formally called Human gammaherpesvirus 4, is one of the nine known human herpesvirus types in the herpes family, and is one of the most common viruses in humans. EBV is a double-stranded DNA virus. [2] Epstein–Barr virus (EBV) is the first identified oncogenic virus, or a virus that can cause cancer. EBV ...
There are two types of oncogenic retroviruses: acute transforming viruses and non-acute transforming viruses. Acute transforming viruses induce a rapid tumor growth since they carry viral oncogenes in their DNA/RNA to induce such growth. An example of an acute transforming virus is the Rous Sarcoma Virus (RSV) that carry the v-src oncogene.
Rous sarcoma virus (RSV) (/ r aʊ s /) is a retrovirus and is the first oncovirus to have been described. It causes sarcoma in chickens. As with all retroviruses, it reverse transcribes its RNA genome into cDNA before integration into the host DNA.
HSV1716 is a first generation oncolytic virus developed by the Glasgow Institute of Virology, and subsequently by Virttu Biologics (formerly Crusade Laboratories, a spin-out from The Institute of Virology), to selectively destroy cancer cells. The virus has the trade name SEPREHVIR. It is based on the herpes simplex virus (HSV-1).